The expression of the SMC family is closely associated with B cells, CD4+ T cells, CD8+ T cells, macrophages, neutrophils, and DCs (49), which can be potential therapeutic targets for HCC, and it has been demonstrated that inhibitors targeting SMC2, SMC3, and SMC4 can be a practical therapeutic strategy for HCC (50, 51). Here, SMC2 is linked to hepatocellular carcinoma.